CHEST 2025: INSIDE LOOK
- This event has passed.
COPD Case Discussions: Eosinophils as a Biomarker of Type 2 Inflammation That Predicts Therapeutic Response
October 20 from 2:30 pm – 3:15 pm CDT
Learning Theater 1
Sponsored by Regeneron & Sanofi
Program Description
Blood eosinophil count can be a clinically valuable biomarker of type 2 inflammation in COPD, but is impacted by many factors. Join us for a case-based discussion on type 2 inflammation and how considering biomarkers can address exacerbations and lung function in patients with COPD. This interactive session challenges you to decide what to do when triple therapy is not enough and introduces a treatment option that addresses sources of type 2 inflammation.
This is a non-CME event and does not qualify for CME or CE, or MOC credit. This event is not part of the official CHEST Annual Meeting 2025 conference sessions. This event is not an endorsement by CHEST and does not reflect the views or opinions of CHEST.
Presenters
Bryan Krajicek, MD, FCCP
Creighton University College of Medicine
Associate Professor of Medicine
Omaha, Nebraska
Jacqueline B. Sutter, DO
Mainline Health
Pulmonary, Critical Care & Advanced Bronchoscopy Division
Wynnewood, Pennsylvania
Medicine Thomas Jefferson University
Clinical Assistant Professor of Medicine
Philadelphia, Pennsylvania
